Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study

समान संसाधन

• Supplementary Table S4 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
  द्वारा: Takafumi Koyama (15035714)
  प्रकाशित: (2025)
• Supplementary Table S6 from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
  द्वारा: Takafumi Koyama (15035714)
  प्रकाशित: (2025)
• Supplementary Table S5A from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study
  द्वारा: Takafumi Koyama (15035714)
  प्रकाशित: (2025)
• Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
  द्वारा: Nam Q. Bui (14958210)
  प्रकाशित: (2025)
• Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
  द्वारा: Srivandana Akshintala (16610490)
  प्रकाशित: (2025)